Fierce Biotech

The biopharma industry is rapidly evolving, with innovative concepts emerging every day. Subscribers turn to FierceBiotech as their essential resource for up-to-date news, insights, and information regarding biotechnology and pharmaceutical research and development. Each business day, FierceBiotech and its associated publications provide comprehensive coverage of the drug development and MedTech sectors. This includes everything from early-stage scientific research and initial funding rounds to IPOs, licensing agreements, clinical trials, regulatory updates, mergers, and acquisitions, and much more.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#80315

United States

#22369

Health/Biotechnology and Pharmaceuticals

#16

Traffic sources

Monthly visitors

Articles

Trump administration axes $450M more in grant funding to Harvard

2 days ago | fiercebiotech.com | Darren Incorvaia

The federal government is slashing $450 million in grant funding to Harvard University, adding on to the $2.2 billion that has already been cut, according to a May 13 statement from the U.S. Department of Health and Human Services (HHS). The decision to revoke further funding stems in part from recent accusations from the Trump administration that the Harvard Law Review discriminated against white applicants when choosing which articles to publish and members to admit.
Roche to spend $550M building Indianapolis HQ into CGM production hub

2 days ago | fiercebiotech.com | Conor Hale

Roche plans to invest as much as $550 million in its Indianapolis diagnostics campus during the next five years, with plans to build it into a U.S. manufacturing and distribution hub for its wearable diabetes blood sugar sensors.
Labcorp CRO spinout Fortrea says farewell to inaugural CEO as stock declines further

3 days ago | fiercebiotech.com | Darren Incorvaia

North Carolina-based CRO Fortrea is saying goodbye to its CEO. Thomas Pike is hitting the road effective May 13 and will be replaced in the interim by Peter Neupert, Fortrea’s lead independent director. A search for Pike’s permanent successor is already in the advanced stages, Fortrea said in a May 12 release. Pike will stay at the company as a consultant to help with the leadership transition. Fortrea was spun out of Labcorp in July 2023 with Pike at the helm.
Former Inhibikase leader launches new biotech for midstage Parkinson’s asset

3 days ago | fiercebiotech.com | Darren Incorvaia

The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered Parkinson’s candidate over the finish line. Milton Werner, Ph.D., is the founder and CEO of newly launched ABLi Therapeutics, which aims to develop a candidate called risvodetinib as a disease-modifying therapy for Parkinson’s and other diseases of the Abelson Tyrosine Kinases (c-Abl).
Capsule endoscopy developer CapsoVision files $30 million IPO

3 days ago | fiercebiotech.com | Conor Hale

CapsoVision has filed to go public, with plans to raise up to $30 million to support the development of its swallowable capsule camera and screening programs for gastrointestinal diseases, cancers and internal bleeding.
NGM Bio slims down in strategic pivot, cutting 75% of staff and halting a midstage liver disease program

3 days ago | fiercebiotech.com | Darren Incorvaia

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of a phase 2 liver disease asset and halting further investment in discovery and preclinical work, the company confirmed in a statement to Fierce Biotech. The company’s CEO David Woodhouse, Ph.D., has also voluntarily decided to step down, with Vice President of Corporate Development Diana Peng Bockus stepping up to take his place.
FDA approves Teal Health’s HPV screening test as an at-home alternative to the Pap smear

6 days ago | fiercebiotech.com | Conor Hale

The FDA has approved its first at-home collection kit that allows women to screen themselves for human papillomavirus and cervical cancer risk by mailing a sample to a lab—where it is analyzed by the same Pap smear test used in clinics. Developed by Teal Health, the Teal Wand is available with a prescription. It uses a sponge-like swab to gather a sample from within the vagina, with no speculum required.
Eli Lilly expands Purdue University partnership with $250M investment

6 days ago | fiercebiotech.com | Darren Incorvaia

Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with Purdue University over the next eight years. The boosted pact with the boilermakers will focus on artificial intelligence drug discovery methods, speeding up the process of moving drugs through clinical trials and into regulatory approval and manufacturing and enhancing the Indiana life sciences workforce, according to a May 9 release.
Imperative Care launches dual-catheter stroke aspiration system

6 days ago | fiercebiotech.com | Conor Hale

Following the FDA’s clearance earlier this year of its large-bore catheter for removing oxygen-blocking blood clots, Imperative Care is rolling out a new technique for treating stroke that combines two of its systems. The company said its Zoom DuoPort approach enables uninterrupted aspiration during thrombectomy by connecting two catheters to a single vacuum source dubbed the continuous dual aspiration technique, or CDAT.
Vir's 'functional cure' candidate for hepatitis B misses mark in phase 2

6 days ago | fiercebiotech.com | Gabrielle Masson

The investigational combo of Vir’s monoclonal antibody tobevibart and Alnylam-discovered siRNA elebsiran was measured in a phase 2 trial for patients with chronic hepatitis B (CHB). Participants received the combo with or without pegylated interferon alpha (PEG-IFNα), a medication used to fight off CHB. Patients were placed into one of 13 specific cohorts, according to ClinicalTrials.gov.